Adragos is the globally operating investment arm of a German Family Office. The investment focus lies solely on the pharmaceutical industry.
WE ONLY DO PHARMA, SOLELY INVEST IN PRIVATE ASSETS OUTSIDE CAPITAL MARKETS AND ALWAYS ACQUIRE 100 % OWNERSHIP.
It is our strong conviction that real value creation requires a deep understanding of the industry one operates in, especially in highly regulated environments. That is why we focus exclusively on the pharmaceutical sector. Our special emphasis is on so-called CDMOs (contract development and manufacturing organizations), third-party providers to the pharma industry, located mainly in Europe and North America.
WE COMBINE CAPITAL AND PEOPLE IN CAREFULLY SELECTED, EXTREMELY ATTRACTIVE INVESTMENT OPPORTUNITIES.
Our key to success is the close alignment of interests from equity owners and operational management team. We do not believe in untimely and overly aggressive transformations but in long-term, sustainable value creation. During our holding period, we set the right strategy, drive bolt-on acquisitions and execute targeted operational improvements in a cooperative management approach.
IN ADDITION, TO CREATING FINANCIAL VALUE FOR INVESTORS, WE BUILD BUSINESSES WITH FUNDAMENTAL VALUE FOR OUR HEALTHCARE SYSTEMS.
We do not acquire distressed assets for turnaround but invest in high-quality, undervalued companies. We aim at a holding period of seven years and assure flexibility due to limited reliance on debt financing. The returns for our investors are very atttractive in comparison to stock markets, while the investments are in low-risk businesses that have fundamental value for society.